Astria Therapeutics, Inc. (ATXS) Misses Q2 EPS by 8c

Astria Therapeutics, Inc. (NASDAQ: ATXS) reported Q2 EPS of ($0.57), $0.08 worse than the analyst estimate of ($0.49).

For earnings history and earnings-related data on Astria Therapeutics, Inc. (ATXS) click here.

You May Also Be Interested In

• Dell’s earning report was bullish for Intel CPU demand, analyst says
• Silicon Labs opens new R&D lab in Austin with $23M state grant
• NHTSA opens probe into Tesla Cybercab self-certification